Related Experiment Video
Updated: Jun 1, 2026
Isolation, Purification, and Differentiation of Osteoclast Precursors from Rat Bone Marrow
Published on: May 19, 2019
Inhibition of osteoclast differentiation and bone resorption by N-methylpyrrolidone
Chafik Ghayor1, Rita M Correro, Katrin Lange
1Oral Biotechnology and Bioengineering, Department of Cranio-Maxillofacial Surgery, University Hospital Zurich, University of Zurich, 8091 Zürich, Switzerland.
Abstract:
Regulation of RANKL (receptor activator of nuclear factor κB ligand)-induced osteoclast differentiation is of current interest in the development of antiresorptive agents. Osteoclasts are multinucleated cells that play a crucial role in bone resorption. In this study, we investigated the effects of N-methylpyrrolidone (NMP) on the regulation of RANKL-induced osteoclastogenesis. NMP inhibited RANKL-induced tartrate-resistant acid phosphatase activity and the formation of tartrate-resistant acid phosphatase-positive multinucleated cells. The RANKL-induced expression of NFATc1 (nuclear factor of activated T cells, cytoplasmic 1) and c-Fos, which are key transcription factors for osteoclastogenesis, was also reduced by treatment with NMP. Furthermore, NMP induced disruption of the actin rings and decreased the mRNAs of cathepsin K and MMP-9 (matrix metalloproteinase-9), both involved in bone resorption. Taken together, these results suggest that NMP inhibits osteoclast differentiation and attenuates bone resorption. Therefore, NMP could prove useful for the treatment of osteoporosis or other bone diseases associated with excessive bone resorption.
Insights
N-methylpyrrolidone (NMP) effectively inhibits osteoclast differentiation and bone resorption by blocking key signaling pathways. This suggests NMP
Area of Science:
- Bone Biology and Disease
- Pharmacology
- Cellular Signaling
Background:
- Osteoclast differentiation, regulated by RANKL, is critical for bone resorption and implicated in diseases like osteoporosis.
- Antiresorptive agents targeting osteoclasts are essential for managing bone loss.
Purpose of the Study:
- To investigate the effects of N-methylpyrrolidone (NMP) on RANKL-induced osteoclastogenesis.
- To determine NMP's potential as an antiresorptive agent.
Main Methods:
- Assessing tartrate-resistant acid phosphatase (TRAP) activity and multinucleated cell formation.
- Quantifying the expression of key osteoclastogenic transcription factors (NFATc1, c-Fos).
- Analyzing the impact of NMP on actin ring disruption and the mRNA levels of bone resorption markers (Cathepsin K, MMP-9).
Main Results:
- NMP significantly inhibited RANKL-induced TRAP activity and multinucleated osteoclast formation.
- NMP reduced the expression of NFATc1 and c-Fos, crucial for osteoclastogenesis.
- NMP disrupted osteoclast actin rings and decreased Cathepsin K and MMP-9 mRNA levels, indicating reduced bone resorption capacity.
Conclusions:
- N-methylpyrrolidone (NMP) demonstrates potent inhibitory effects on osteoclast differentiation and function.
- NMP attenuates bone resorption by interfering with essential signaling pathways and cellular processes.
- NMP shows promise as a therapeutic agent for osteoporosis and other bone diseases characterized by excessive bone resorption.
Related Concept Videos
01:31Osteoclasts in Bone Remodeling
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:40Bone Remodeling
01:15Drugs that Stabilize Microtubules
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...